Medicinova (MNOV) MN-166 Trial in ALS Met Primary Safety and Tolerability Endpoint
Tweet Send to a Friend
MediciNova, Inc., (NASDAQ: MNOV) today announced positive top-line results from MediciNova’s clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
